Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 5/20 | 0.42 |
| ▸ | CTSK | P43235 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9670280 | 0.91 | AAK1 (0.52) | AAK1HDAC1LMNAPOLBCTSS | |
| SCHEMBL9744622 | 0.87 | CTSS (0.55) | AAK1HDAC1LMNAPOLBCTSS | |
| SCHEMBL9283981 | 0.86 | AAK1 (0.51) | AAK1HDAC1LMNAPOLBCTSS | |
| SCHEMBL9286086 | 0.86 | AAK1 (0.51) | AAK1HDAC1LMNAPOLBCTSS | |
| SCHEMBL38662963 | 0.82 | AAK1 (0.53) | AAK1HDAC1LMNAPOLBCTSS | |
| SCHEMBL5349230 | 0.82 | HDAC1 (0.48) | AAK1HDAC1CTSSCTSKCTSL | |
| SCHEMBL29353000 | 0.79 | HDAC1 (0.52) | HDAC1LMNAPOLB | |
| SCHEMBL211033 | 0.79 | HDAC1 (0.52) | HDAC1LMNAPOLB | |
| SCHEMBL4080656 | 0.79 | AAK1 (0.55) | AAK1HDAC1CTSSCTSKTP53 | |
| SCHEMBL10206290 | 0.78 | HDAC1 (0.46) | HDAC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822474-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | POUZET PASCALE (US) | 2012-05-03 | — | — | US | disclosed |
| US-8114878-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-14 | — | — | US | disclosed |
| WO-2007118793-A1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | WO | disclosed |
| EP-1847543-A1 | Dihydrothienopyrimidines for the treatment of inflammatory diseases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | DPYD, DHFR, TPMT | AAK1 2727/4885HDAC1 2359/4885LMNA 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.